Insurers lead European
shares higher as Hurricane Irma weakens
Send a link to a friend
[September 11, 2017]
By Danilo Masoni
MILAN (Reuters) - European shares rose on
Monday, led by insurers as the downgrade of Hurricane Irma in the United
States raised the prospect that costs for the industry may be lower than
initially feared.
Europe's insurance index was the biggest sectoral gainer, up 2 percent
and set for its best day in more than four months after the estimated
insured loss in the U.S. resulting from Irma was cut to $20-40 billion.
"Insured losses (overall) are now expected to be less than many feared,"
Credit Suisse analysts said.
Their gains added fuel to a broad-based rally, helping the pan-European
STOXX 600 rise 0.6 percent.
Irma, which hit Florida early on Sunday, came swiftly after Hurricane
Harvey, whose costs for the industry have been estimated at $20-$30
billion.

Among top gainers were top world reinsurers Munich Re, Swiss Re and
Hannover Re, all up over 4 percent, while Britain's Beazley added 6
percent.
Analysts at Baader Helvea upgraded Hannover Re to hold from sell, saying
that following the stock's recent heavy losses the market had already
priced in an extremely severe scenario.
[to top of second column] |

Traders sit at their desks in front of the DAX board at the
Frankfurt stock exchange, Germany, June 29, 2015. REUTERS/Ralph
Orlowski

Europe's insurance index has underperformed the broader market so far in 2017
and is still down 4.5 percent from its year high, hit in early August.
Elsewhere, pharma heavyweight AstraZeneca rose 2.3 percent after two of its
drugs tackling lung cancer delivered impressive clinical results on Saturday.
That helped the British group offset a big clinical trial setback in the disease
in July that sent its shares down more than 15 percent, its biggest daily loss
ever.
In the same sector, however, Denmark's Lundbeck slumped 11 percent, the leading
faller in Europe, after the resignation of CEO Kåre Schultz.
(Reporting by Danilo Masoni, Editing by Kit Rees and Mark Trevelyan)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |